132 related articles for article (PubMed ID: 35038545)
1. hnRNPK/Beclin1 signaling regulates autophagy to promote imatinib resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia cells.
Zhang J; Liu X; Yin C; Zong S
Exp Hematol; 2022 Apr; 108():46-54. PubMed ID: 35038545
[TBL] [Abstract][Full Text] [Related]
2. [The Effect of hnRNPK/Beclin1 Signaling on the Drug Resistance of Imatinib in Ph
Zhang JF; Liu XL; Zong S
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):750-754. PubMed ID: 35680800
[TBL] [Abstract][Full Text] [Related]
3. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
4. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
[TBL] [Abstract][Full Text] [Related]
5. The role of heterogeneous nuclear ribonucleoprotein K in the progression of chronic myeloid leukemia.
Du Q; Wang L; Zhu H; Zhang S; Xu L; Zheng W; Liu X
Med Oncol; 2010 Sep; 27(3):673-9. PubMed ID: 19653139
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous nuclear ribonucleoprotein K promotes the progression of lung cancer by inhibiting the p53-dependent signaling pathway.
Li M; Yang X; Zhang G; Wang L; Zhu Z; Zhang W; Huang H; Gao R
Thorac Cancer; 2022 May; 13(9):1311-1321. PubMed ID: 35352475
[TBL] [Abstract][Full Text] [Related]
7. hnRNPK modulates selective quality-control autophagy by downregulating the expression of HDAC6 in 293 cells.
Li Z; Liu X; Ma J; Zhang T; Gao X; Liu L
Int J Oncol; 2018 Nov; 53(5):2200-2212. PubMed ID: 30106132
[TBL] [Abstract][Full Text] [Related]
8. Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL.
Guo Y; Li Y; Xiang B; Huang XO; Ma HB; Wang FF; Gong YP
Biochem J; 2017 Dec; 474(24):4153-4170. PubMed ID: 29046392
[TBL] [Abstract][Full Text] [Related]
9. Regulatory mechanism of interaction between Y-box-binding protein 1 and heterogenous nuclear ribonucleoprotein K in cell division cycle 25a signal pathway and lung cancer metastasis.
Fu L; Yang M; Ma Y
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):62-68. PubMed ID: 38279484
[TBL] [Abstract][Full Text] [Related]
10. The autophagy induced by curcumin via MEK/ERK pathway plays an early anti-leukemia role in human Philadelphia chromosome-positive acute lymphoblastic leukemia SUP-B15 cells.
Guo Y; Shan QQ; Gong PY; Wang SC
J Cancer Res Ther; 2018; 14(Supplement):S125-S131. PubMed ID: 29578162
[TBL] [Abstract][Full Text] [Related]
11. Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia.
Guo Y; Li Y; Shan Q; He G; Lin J; Gong Y
Int J Biochem Cell Biol; 2015 Aug; 65():1-11. PubMed ID: 25979368
[TBL] [Abstract][Full Text] [Related]
12. [The Roles of Glut5 in Imatinib Resistance in the Ph
Yan TY; Naren DL; Gong YP
Sichuan Da Xue Xue Bao Yi Xue Ban; 2017 May; 48(3):389-393. PubMed ID: 28616912
[TBL] [Abstract][Full Text] [Related]
13. In vitro drug resistance to imatinib and mutation of ABL gene in childhood Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
Kawaguchi H; Taketani T; Hongo T; Park MJ; Koh K; Ida K; Kobayashi M; Takita J; Taki T; Yoshino H; Bessho F; Hayashi Y
Leuk Lymphoma; 2005 Feb; 46(2):273-6. PubMed ID: 15621812
[TBL] [Abstract][Full Text] [Related]
14. CD9 knockdown suppresses cell proliferation, adhesion, migration and invasion, while promoting apoptosis and the efficacy of chemotherapeutic drugs and imatinib in Ph+ ALL SUP‑B15 cells.
Xing C; Xu W; Shi Y; Zhou B; Wu D; Liang B; Zhou Y; Gao S; Feng J
Mol Med Rep; 2020 Oct; 22(4):2791-2800. PubMed ID: 32945456
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
Czyz A; Lewandowski K; Kroll R; Komarnicki M
Med Oncol; 2010 Dec; 27(4):1123-6. PubMed ID: 19885746
[TBL] [Abstract][Full Text] [Related]
16. Huaier extract enhances the treatment efficacy of imatinib in Ik6
Qu P; Han J; Qiu Y; Yu H; Hao J; Jin R; Zhou F
Biomed Pharmacother; 2019 Sep; 117():109071. PubMed ID: 31202171
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous Nuclear Ribonucleoprotein K Is Involved in the Estrogen-Signaling Pathway in Breast Cancer.
Iwabuchi E; Miki Y; Suzuki T; Hirakawa H; Ishida T; Sasano H
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33806648
[TBL] [Abstract][Full Text] [Related]
18. Targeting miR-21 sensitizes Ph+ ALL Sup-b15 cells to imatinib-induced apoptosis through upregulation of PTEN.
Wang WZ; Lin XH; Pu QH; Liu MY; Li L; Wu LR; Wu QQ; Mao JW; Zhu JY; Jin XB
Biochem Biophys Res Commun; 2014 Nov; 454(3):423-8. PubMed ID: 25451263
[TBL] [Abstract][Full Text] [Related]
19. Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells.
Liu J; Zhang Y; Liu A; Wang J; Li L; Chen X; Gao X; Xue Y; Zhang X; Liu Y
Int J Mol Sci; 2016 Apr; 17(4):531. PubMed ID: 27070592
[TBL] [Abstract][Full Text] [Related]
20. Novel oncogene COPS3 interacts with Beclin1 and Raf-1 to regulate metastasis of osteosarcoma through autophagy.
Zhang F; Yan T; Guo W; Sun K; Wang S; Bao X; Liu K; Zheng B; Zhang H; Ren T
J Exp Clin Cancer Res; 2018 Jul; 37(1):135. PubMed ID: 29970115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
